Global Heart Hub’s Post

Coronary angioplasty is a procedure to open clogged blood vessels of the heart. Coronary angioplasty treats vessels, called coronary arteries, which deliver blood to heart muscles. On 16 September 1977 the first coronary angioplasty was performed by Dr. Andreas Grüntzig at the University Hospital Zurich in Switzerland. Since then, angioplasty has been the procedure that improves health, increases life expectancy and improves the quality of life.   16 September is the International Day for Interventional Cardiology to raise public awareness of cardiovascular diseases, procedures, related complications, prevention and care. Prove Clinical Labs is well equipped to support Phase I-III Clinical Trials in Cardiovascular Diseases. Find out more about Prove labs and how we can support your clinical trial by visiting: www.provelabs.com #cardiovascular #heartdisease #clinicalresearch #centrallab

Tourmaline Bio has just presented our latest poster at the American Society for Preventive Cardiology (ASPC) Congress, highlighting the design and rationale of our Phase 2 TRANQUILITY trial. This trial builds on data from six previous studies and is an important step forward in understanding how IL-6 pathway inhibition could lower cardiovascular risk in high-risk patients with chronic kidney disease. Read more about the TRANQUILITY trial design here: https://bit.ly/46uyukY #ASPC2024 #clinicaltrial #drugdiscovery

#RhAPP2024 Whew! That’s a “RhAPP!” Another engaging and educational annual CME conference comes to a close. This year I co-presented with a fabulous cardiology colleague, Laura Ross PA-C, on cardiac disease in rheumatologic conditions. We reviewed prevalence of CVD in auto inflammatory conditions with a focus on prevention, discussed updates in treatment of recurring pericarditis in lupus and lastly compared newer algorithms and screening guidelines to detect asymptomatic pulmonary arterial hypertension in scleroderma. https://lnkd.in/gYB5nYUb

More accurate tools for cardiology leaders will do great help in efficiency and diagnosis, also build more confidence in virtual care.

OUT NOW 🎙️New episode from our 💡Innovations in Cardiology💡 series! Dr C. C. Michael Gibson, M.S., M.D. joins host Dr Dipti Itchhaporia, M.D., MACC, FAHA, FESC to discuss the latest advancements and future directions in cardiovascular innovation for 2024. 🎧 Listen Here 👉 https://ow.ly/AMIs50TMENf 🎥 Watch Here 👉 https://ow.ly/n4Ho50TMENe 📊 Topics include strategies to enhance research through direct-to-patient trials, long-term patient monitoring, the potential for personalised care plans and more. #CardioEd #MedEd

At #ESCCongress, the European Society of Cardiology's dedicated Task Force unveiled 2024 guidelines, Class I Level of Evidence A, highlighting IVUS as a key component of a #ModernPCI strategy that enhances patient outcomes. Intracoronary imaging is recommended for managing complex cases particularly left main disease, bifurcations, and long lesions. Explore the full guidelines here: https://lnkd.in/ehjCvNzn

🌟 #ESCCongress 2024 Highlights: Insights from Hotline 8 Session🌟 🔹 #SENIOR-RITA Trial: The largest trial to date in patients aged 75+ with #NSTEMI. While no significant reduction in cardiovascular death or non-fatal MI was observed with an invasive strategy, there was a notable reduction in non-fatal MIs and revascularization procedures. These results empower older patients and clinicians to make informed decisions on invasive management. 🔹 #EARTH-STEMI: This meta-analysis revealed that complete revascularization significantly reduces cardiovascular events compared to culprit-only revascularization in older patients with #STEMI and multivessel disease, with a similar safety profile. Long-term benefits, however, still require further follow-up. 🔹 #SCOFF Trial: Challenging conventional wisdom, this study found that patients who did not fast before cardiac catherisation procedures had no increase in complications and reported higher satisfaction. These findings could lead to updated guidelines, prioritizing patient comfort without compromising safety. These studies collectively pave the way for refined treatment strategies and improved patient care in cardiology.

Today’s cardiovascular case study is a PCI treatment for an elderly patient with a history of stroke.   The patient is an 89-year-old female with complaint of recurring chest tightness for 3 months, that has worsened for the last 3 days. She has a history of 30-year hypertension, hyperlipidemia for more than 20 years, and cerebral infarction that happened more than 10 years ago. The diagnosis confirmed the coronary heart disease with unstable angina.   Old age and past stroke (more than 6 months before PCI) are two minor ARC-HBR criteria. However, the patient’s CRUSADE score was graded as 43, which indicates high bleeding risk.   Thus, a balanced solution between the ischemic and bleeding risks needs to be considered. By choosing the BioFreedom™ stent with post-PCI DAPT treatment of only one month, the patient’s postoperative medication will offer excellent compromise between short term safety and long-term benefits.   A 2.75x18mm BioFreedom™ stent was implanted in the distal LCX. The results were satisfactory. The BioFreedom™ stent has become the recommended treatment stent for patients with high bleeding risks in Europe. It is a suitable choice for short DAPT scenarios, including patients with old age and previous history of stoke. #PCI #cardiovascular #cardiology #DAPT #biofreedom #HBR #healthcare

New Research Discovery! Two inflammatory markers, interleukin-4 and interleukin-17, independently predict heart disease risk, offering valuable insights for diagnosis and treatment. Low levels of these markers are associated with coronary artery disease (CAD), potentially serving as a diagnostic tool to guide patient referral for angiography. This study sheds light on the role of inflammation in cardiovascular health and underscores the importance of exploring new diagnostic avenues. [Link: https://hubs.li/Q02mWGt60 As a comprehensive cardiology platform, RhythmScience is committed to empowering physicians and clinical teams to manage patients with heart failure effectively. We're thrilled to see heart failure research that reveals new insights with the potential to enhance patient care! Learn more about RhythmScience's software & services for cardiac remote monitoring (HF/HTN/Rhythm Management): https://hubs.li/Q02mWtPF0 #HeartHealth #cardiacdatamanagement #remotecardiology #remotemonitoring #cardiology #heartfailure #healthtech #cardiacdata #cardiacmonitoring #epeeps #heart #health #CardiacFacts #HeartFactFriday #patientcare #afib

Shared Decision-making and #SevereAorticStenosis #CME: Webinar explores the process of effective SDM in patients who may be candidates for #TAVR. Available at the Cardiology Advisor Institute. https://brnw.ch/21wLOYL